Key Insights
- Seladelpar, a bile acid synthesis suppressant, has shown promising results in treating primary biliary cholangitis (PBC). In a phase 3 international study, patients who were intolerant or nonresponsive to ursodeoxycholic acid showed significant improvement in biochemical markers with Seladelpar, achieving primary endpoints with a favorable safety profile.
- Apraglutide, a GLP-2 analog with a long half-life of approximately 72 hours, demonstrated significant efficacy in reducing parenteral support requirements for patients with short bowel syndrome. The phase 3 trial showed that weekly administration of Apraglutide was safe and effective, offering a significant advantage over the previously approved teduglutide, which requires daily injections.
- The largest study to date on blood-based colorectal cancer screening evaluated blood samples and colonoscopy data from 27,010 patients. The study achieved a sensitivity of 79.2% for colon cancer detection and a specificity of 91.5% for non-advanced colorectal neoplasia. This indicates a promising future for non-invasive blood tests in colorectal cancer screening, potentially improving early detection and patient compliance.